1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Multivalent Influenza Vaccines Annual Sales 2020-2031 2.1.2 World Current & Future Analysis for Multivalent Influenza Vaccines by Geographic Region, 2020, 2024 & 2031 2.1.3 World Current & Future Analysis for Multivalent Influenza Vaccines by Country/Region, 2020, 2024 & 2031 2.2 Multivalent Influenza Vaccines Segment by Type 2.2.1 Trivalent Inactivated Influenza Vaccine (IIV3) 2.2.2 Trivalent Live Attenuated Vaccine (LAIV3) 2.2.3 Quadrivalent Inactivated Influenza Vaccine (IIV4) 2.3 Multivalent Influenza Vaccines Sales by Type 2.3.1 Global Multivalent Influenza Vaccines Sales Market Share by Type (2020-2025) 2.3.2 Global Multivalent Influenza Vaccines Revenue and Market Share by Type (2020-2025) 2.3.3 Global Multivalent Influenza Vaccines Sale Price by Type (2020-2025) 2.4 Multivalent Influenza Vaccines Segment by Application 2.4.1 6 Months to 3 Years 2.4.2 Above 3 Years 2.5 Multivalent Influenza Vaccines Sales by Application 2.5.1 Global Multivalent Influenza Vaccines Sale Market Share by Application (2020-2025) 2.5.2 Global Multivalent Influenza Vaccines Revenue and Market Share by Application (2020-2025) 2.5.3 Global Multivalent Influenza Vaccines Sale Price by Application (2020-2025) 3 Global by Company 3.1 Global Multivalent Influenza Vaccines Breakdown Data by Company 3.1.1 Global Multivalent Influenza Vaccines Annual Sales by Company (2020-2025) 3.1.2 Global Multivalent Influenza Vaccines Sales Market Share by Company (2020-2025) 3.2 Global Multivalent Influenza Vaccines Annual Revenue by Company (2020-2025) 3.2.1 Global Multivalent Influenza Vaccines Revenue by Company (2020-2025) 3.2.2 Global Multivalent Influenza Vaccines Revenue Market Share by Company (2020-2025) 3.3 Global Multivalent Influenza Vaccines Sale Price by Company 3.4 Key Manufacturers Multivalent Influenza Vaccines Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Multivalent Influenza Vaccines Product Location Distribution 3.4.2 Players Multivalent Influenza Vaccines Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for Multivalent Influenza Vaccines by Geographic Region 4.1 World Historic Multivalent Influenza Vaccines Market Size by Geographic Region (2020-2025) 4.1.1 Global Multivalent Influenza Vaccines Annual Sales by Geographic Region (2020-2025) 4.1.2 Global Multivalent Influenza Vaccines Annual Revenue by Geographic Region (2020-2025) 4.2 World Historic Multivalent Influenza Vaccines Market Size by Country/Region (2020-2025) 4.2.1 Global Multivalent Influenza Vaccines Annual Sales by Country/Region (2020-2025) 4.2.2 Global Multivalent Influenza Vaccines Annual Revenue by Country/Region (2020-2025) 4.3 Americas Multivalent Influenza Vaccines Sales Growth 4.4 APAC Multivalent Influenza Vaccines Sales Growth 4.5 Europe Multivalent Influenza Vaccines Sales Growth 4.6 Middle East & Africa Multivalent Influenza Vaccines Sales Growth 5 Americas 5.1 Americas Multivalent Influenza Vaccines Sales by Country 5.1.1 Americas Multivalent Influenza Vaccines Sales by Country (2020-2025) 5.1.2 Americas Multivalent Influenza Vaccines Revenue by Country (2020-2025) 5.2 Americas Multivalent Influenza Vaccines Sales by Type (2020-2025) 5.3 Americas Multivalent Influenza Vaccines Sales by Application (2020-2025) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Multivalent Influenza Vaccines Sales by Region 6.1.1 APAC Multivalent Influenza Vaccines Sales by Region (2020-2025) 6.1.2 APAC Multivalent Influenza Vaccines Revenue by Region (2020-2025) 6.2 APAC Multivalent Influenza Vaccines Sales by Type (2020-2025) 6.3 APAC Multivalent Influenza Vaccines Sales by Application (2020-2025) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Multivalent Influenza Vaccines by Country 7.1.1 Europe Multivalent Influenza Vaccines Sales by Country (2020-2025) 7.1.2 Europe Multivalent Influenza Vaccines Revenue by Country (2020-2025) 7.2 Europe Multivalent Influenza Vaccines Sales by Type (2020-2025) 7.3 Europe Multivalent Influenza Vaccines Sales by Application (2020-2025) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Multivalent Influenza Vaccines by Country 8.1.1 Middle East & Africa Multivalent Influenza Vaccines Sales by Country (2020-2025) 8.1.2 Middle East & Africa Multivalent Influenza Vaccines Revenue by Country (2020-2025) 8.2 Middle East & Africa Multivalent Influenza Vaccines Sales by Type (2020-2025) 8.3 Middle East & Africa Multivalent Influenza Vaccines Sales by Application (2020-2025) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Multivalent Influenza Vaccines 10.3 Manufacturing Process Analysis of Multivalent Influenza Vaccines 10.4 Industry Chain Structure of Multivalent Influenza Vaccines 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Multivalent Influenza Vaccines Distributors 11.3 Multivalent Influenza Vaccines Customer 12 World Forecast Review for Multivalent Influenza Vaccines by Geographic Region 12.1 Global Multivalent Influenza Vaccines Market Size Forecast by Region 12.1.1 Global Multivalent Influenza Vaccines Forecast by Region (2026-2031) 12.1.2 Global Multivalent Influenza Vaccines Annual Revenue Forecast by Region (2026-2031) 12.2 Americas Forecast by Country (2026-2031) 12.3 APAC Forecast by Region (2026-2031) 12.4 Europe Forecast by Country (2026-2031) 12.5 Middle East & Africa Forecast by Country (2026-2031) 12.6 Global Multivalent Influenza Vaccines Forecast by Type (2026-2031) 12.7 Global Multivalent Influenza Vaccines Forecast by Application (2026-2031) 13 Key Players Analysis 13.1 Sanofi 13.1.1 Sanofi Company Information 13.1.2 Sanofi Multivalent Influenza Vaccines Product Portfolios and Specifications 13.1.3 Sanofi Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) 13.1.4 Sanofi Main Business Overview 13.1.5 Sanofi Latest Developments 13.2 CSL 13.2.1 CSL Company Information 13.2.2 CSL Multivalent Influenza Vaccines Product Portfolios and Specifications 13.2.3 CSL Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) 13.2.4 CSL Main Business Overview 13.2.5 CSL Latest Developments 13.3 GSK 13.3.1 GSK Company Information 13.3.2 GSK Multivalent Influenza Vaccines Product Portfolios and Specifications 13.3.3 GSK Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) 13.3.4 GSK Main Business Overview 13.3.5 GSK Latest Developments 13.4 Viatris 13.4.1 Viatris Company Information 13.4.2 Viatris Multivalent Influenza Vaccines Product Portfolios and Specifications 13.4.3 Viatris Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) 13.4.4 Viatris Main Business Overview 13.4.5 Viatris Latest Developments 13.5 AstraZeneca 13.5.1 AstraZeneca Company Information 13.5.2 AstraZeneca Multivalent Influenza Vaccines Product Portfolios and Specifications 13.5.3 AstraZeneca Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) 13.5.4 AstraZeneca Main Business Overview 13.5.5 AstraZeneca Latest Developments 13.6 Hualan Bio 13.6.1 Hualan Bio Company Information 13.6.2 Hualan Bio Multivalent Influenza Vaccines Product Portfolios and Specifications 13.6.3 Hualan Bio Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) 13.6.4 Hualan Bio Main Business Overview 13.6.5 Hualan Bio Latest Developments 13.7 Changchun Institute of Biological 13.7.1 Changchun Institute of Biological Company Information 13.7.2 Changchun Institute of Biological Multivalent Influenza Vaccines Product Portfolios and Specifications 13.7.3 Changchun Institute of Biological Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) 13.7.4 Changchun Institute of Biological Main Business Overview 13.7.5 Changchun Institute of Biological Latest Developments 13.8 Sinovac 13.8.1 Sinovac Company Information 13.8.2 Sinovac Multivalent Influenza Vaccines Product Portfolios and Specifications 13.8.3 Sinovac Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) 13.8.4 Sinovac Main Business Overview 13.8.5 Sinovac Latest Developments 13.9 Bcht Biotechnology 13.9.1 Bcht Biotechnology Company Information 13.9.2 Bcht Biotechnology Multivalent Influenza Vaccines Product Portfolios and Specifications 13.9.3 Bcht Biotechnology Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) 13.9.4 Bcht Biotechnology Main Business Overview 13.9.5 Bcht Biotechnology Latest Developments 13.10 Jiangsu GDK 13.10.1 Jiangsu GDK Company Information 13.10.2 Jiangsu GDK Multivalent Influenza Vaccines Product Portfolios and Specifications 13.10.3 Jiangsu GDK Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) 13.10.4 Jiangsu GDK Main Business Overview 13.10.5 Jiangsu GDK Latest Developments 13.11 KM Biologics 13.11.1 KM Biologics Company Information 13.11.2 KM Biologics Multivalent Influenza Vaccines Product Portfolios and Specifications 13.11.3 KM Biologics Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) 13.11.4 KM Biologics Main Business Overview 13.11.5 KM Biologics Latest Developments 13.12 ADIMMUNE Corporation 13.12.1 ADIMMUNE Corporation Company Information 13.12.2 ADIMMUNE Corporation Multivalent Influenza Vaccines Product Portfolios and Specifications 13.12.3 ADIMMUNE Corporation Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) 13.12.4 ADIMMUNE Corporation Main Business Overview 13.12.5 ADIMMUNE Corporation Latest Developments 13.13 Aleph Biomedical 13.13.1 Aleph Biomedical Company Information 13.13.2 Aleph Biomedical Multivalent Influenza Vaccines Product Portfolios and Specifications 13.13.3 Aleph Biomedical Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) 13.13.4 Aleph Biomedical Main Business Overview 13.13.5 Aleph Biomedical Latest Developments 13.14 Shanghai Institute of Biological Products 13.14.1 Shanghai Institute of Biological Products Company Information 13.14.2 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Portfolios and Specifications 13.14.3 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) 13.14.4 Shanghai Institute of Biological Products Main Business Overview 13.14.5 Shanghai Institute of Biological Products Latest Developments 13.15 Zhongyianke Biotech 13.15.1 Zhongyianke Biotech Company Information 13.15.2 Zhongyianke Biotech Multivalent Influenza Vaccines Product Portfolios and Specifications 13.15.3 Zhongyianke Biotech Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) 13.15.4 Zhongyianke Biotech Main Business Overview 13.15.5 Zhongyianke Biotech Latest Developments 13.16 Wuhan Institute of Biological Products 13.16.1 Wuhan Institute of Biological Products Company Information 13.16.2 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Portfolios and Specifications 13.16.3 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2020-2025) 13.16.4 Wuhan Institute of Biological Products Main Business Overview 13.16.5 Wuhan Institute of Biological Products Latest Developments 14 Research Findings and Conclusion
List of Tables Table 1. Multivalent Influenza Vaccines Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions) Table 2. Multivalent Influenza Vaccines Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions) Table 3. Major Players of Trivalent Inactivated Influenza Vaccine (IIV3) Table 4. Major Players of Trivalent Live Attenuated Vaccine (LAIV3) Table 5. Major Players of Quadrivalent Inactivated Influenza Vaccine (IIV4) Table 6. Global Multivalent Influenza Vaccines Sales by Type (2020-2025) & (K Units) Table 7. Global Multivalent Influenza Vaccines Sales Market Share by Type (2020-2025) Table 8. Global Multivalent Influenza Vaccines Revenue by Type (2020-2025) & ($ million) Table 9. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2020-2025) Table 10. Global Multivalent Influenza Vaccines Sale Price by Type (2020-2025) & (US$/Unit) Table 11. Global Multivalent Influenza Vaccines Sale by Application (2020-2025) & (K Units) Table 12. Global Multivalent Influenza Vaccines Sale Market Share by Application (2020-2025) Table 13. Global Multivalent Influenza Vaccines Revenue by Application (2020-2025) & ($ million) Table 14. Global Multivalent Influenza Vaccines Revenue Market Share by Application (2020-2025) Table 15. Global Multivalent Influenza Vaccines Sale Price by Application (2020-2025) & (US$/Unit) Table 16. Global Multivalent Influenza Vaccines Sales by Company (2020-2025) & (K Units) Table 17. Global Multivalent Influenza Vaccines Sales Market Share by Company (2020-2025) Table 18. Global Multivalent Influenza Vaccines Revenue by Company (2020-2025) & ($ millions) Table 19. Global Multivalent Influenza Vaccines Revenue Market Share by Company (2020-2025) Table 20. Global Multivalent Influenza Vaccines Sale Price by Company (2020-2025) & (US$/Unit) Table 21. Key Manufacturers Multivalent Influenza Vaccines Producing Area Distribution and Sales Area Table 22. Players Multivalent Influenza Vaccines Products Offered Table 23. Multivalent Influenza Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) Table 24. New Products and Potential Entrants Table 25. Market M&A Activity & Strategy Table 26. Global Multivalent Influenza Vaccines Sales by Geographic Region (2020-2025) & (K Units) Table 27. Global Multivalent Influenza Vaccines Sales Market Share Geographic Region (2020-2025) Table 28. Global Multivalent Influenza Vaccines Revenue by Geographic Region (2020-2025) & ($ millions) Table 29. Global Multivalent Influenza Vaccines Revenue Market Share by Geographic Region (2020-2025) Table 30. Global Multivalent Influenza Vaccines Sales by Country/Region (2020-2025) & (K Units) Table 31. Global Multivalent Influenza Vaccines Sales Market Share by Country/Region (2020-2025) Table 32. Global Multivalent Influenza Vaccines Revenue by Country/Region (2020-2025) & ($ millions) Table 33. Global Multivalent Influenza Vaccines Revenue Market Share by Country/Region (2020-2025) Table 34. Americas Multivalent Influenza Vaccines Sales by Country (2020-2025) & (K Units) Table 35. Americas Multivalent Influenza Vaccines Sales Market Share by Country (2020-2025) Table 36. Americas Multivalent Influenza Vaccines Revenue by Country (2020-2025) & ($ millions) Table 37. Americas Multivalent Influenza Vaccines Sales by Type (2020-2025) & (K Units) Table 38. Americas Multivalent Influenza Vaccines Sales by Application (2020-2025) & (K Units) Table 39. APAC Multivalent Influenza Vaccines Sales by Region (2020-2025) & (K Units) Table 40. APAC Multivalent Influenza Vaccines Sales Market Share by Region (2020-2025) Table 41. APAC Multivalent Influenza Vaccines Revenue by Region (2020-2025) & ($ millions) Table 42. APAC Multivalent Influenza Vaccines Sales by Type (2020-2025) & (K Units) Table 43. APAC Multivalent Influenza Vaccines Sales by Application (2020-2025) & (K Units) Table 44. Europe Multivalent Influenza Vaccines Sales by Country (2020-2025) & (K Units) Table 45. Europe Multivalent Influenza Vaccines Revenue by Country (2020-2025) & ($ millions) Table 46. Europe Multivalent Influenza Vaccines Sales by Type (2020-2025) & (K Units) Table 47. Europe Multivalent Influenza Vaccines Sales by Application (2020-2025) & (K Units) Table 48. Middle East & Africa Multivalent Influenza Vaccines Sales by Country (2020-2025) & (K Units) Table 49. Middle East & Africa Multivalent Influenza Vaccines Revenue Market Share by Country (2020-2025) Table 50. Middle East & Africa Multivalent Influenza Vaccines Sales by Type (2020-2025) & (K Units) Table 51. Middle East & Africa Multivalent Influenza Vaccines Sales by Application (2020-2025) & (K Units) Table 52. Key Market Drivers & Growth Opportunities of Multivalent Influenza Vaccines Table 53. Key Market Challenges & Risks of Multivalent Influenza Vaccines Table 54. Key Industry Trends of Multivalent Influenza Vaccines Table 55. Multivalent Influenza Vaccines Raw Material Table 56. Key Suppliers of Raw Materials Table 57. Multivalent Influenza Vaccines Distributors List Table 58. Multivalent Influenza Vaccines Customer List Table 59. Global Multivalent Influenza Vaccines Sales Forecast by Region (2026-2031) & (K Units) Table 60. Global Multivalent Influenza Vaccines Revenue Forecast by Region (2026-2031) & ($ millions) Table 61. Americas Multivalent Influenza Vaccines Sales Forecast by Country (2026-2031) & (K Units) Table 62. Americas Multivalent Influenza Vaccines Annual Revenue Forecast by Country (2026-2031) & ($ millions) Table 63. APAC Multivalent Influenza Vaccines Sales Forecast by Region (2026-2031) & (K Units) Table 64. APAC Multivalent Influenza Vaccines Annual Revenue Forecast by Region (2026-2031) & ($ millions) Table 65. Europe Multivalent Influenza Vaccines Sales Forecast by Country (2026-2031) & (K Units) Table 66. Europe Multivalent Influenza Vaccines Revenue Forecast by Country (2026-2031) & ($ millions) Table 67. Middle East & Africa Multivalent Influenza Vaccines Sales Forecast by Country (2026-2031) & (K Units) Table 68. Middle East & Africa Multivalent Influenza Vaccines Revenue Forecast by Country (2026-2031) & ($ millions) Table 69. Global Multivalent Influenza Vaccines Sales Forecast by Type (2026-2031) & (K Units) Table 70. Global Multivalent Influenza Vaccines Revenue Forecast by Type (2026-2031) & ($ millions) Table 71. Global Multivalent Influenza Vaccines Sales Forecast by Application (2026-2031) & (K Units) Table 72. Global Multivalent Influenza Vaccines Revenue Forecast by Application (2026-2031) & ($ millions) Table 73. Sanofi Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors Table 74. Sanofi Multivalent Influenza Vaccines Product Portfolios and Specifications Table 75. Sanofi Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 76. Sanofi Main Business Table 77. Sanofi Latest Developments Table 78. CSL Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors Table 79. CSL Multivalent Influenza Vaccines Product Portfolios and Specifications Table 80. CSL Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 81. CSL Main Business Table 82. CSL Latest Developments Table 83. GSK Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors Table 84. GSK Multivalent Influenza Vaccines Product Portfolios and Specifications Table 85. GSK Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 86. GSK Main Business Table 87. GSK Latest Developments Table 88. Viatris Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors Table 89. Viatris Multivalent Influenza Vaccines Product Portfolios and Specifications Table 90. Viatris Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 91. Viatris Main Business Table 92. Viatris Latest Developments Table 93. AstraZeneca Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors Table 94. AstraZeneca Multivalent Influenza Vaccines Product Portfolios and Specifications Table 95. AstraZeneca Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 96. AstraZeneca Main Business Table 97. AstraZeneca Latest Developments Table 98. Hualan Bio Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors Table 99. Hualan Bio Multivalent Influenza Vaccines Product Portfolios and Specifications Table 100. Hualan Bio Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 101. Hualan Bio Main Business Table 102. Hualan Bio Latest Developments Table 103. Changchun Institute of Biological Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors Table 104. Changchun Institute of Biological Multivalent Influenza Vaccines Product Portfolios and Specifications Table 105. Changchun Institute of Biological Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 106. Changchun Institute of Biological Main Business Table 107. Changchun Institute of Biological Latest Developments Table 108. Sinovac Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors Table 109. Sinovac Multivalent Influenza Vaccines Product Portfolios and Specifications Table 110. Sinovac Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 111. Sinovac Main Business Table 112. Sinovac Latest Developments Table 113. Bcht Biotechnology Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors Table 114. Bcht Biotechnology Multivalent Influenza Vaccines Product Portfolios and Specifications Table 115. Bcht Biotechnology Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 116. Bcht Biotechnology Main Business Table 117. Bcht Biotechnology Latest Developments Table 118. Jiangsu GDK Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors Table 119. Jiangsu GDK Multivalent Influenza Vaccines Product Portfolios and Specifications Table 120. Jiangsu GDK Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 121. Jiangsu GDK Main Business Table 122. Jiangsu GDK Latest Developments Table 123. KM Biologics Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors Table 124. KM Biologics Multivalent Influenza Vaccines Product Portfolios and Specifications Table 125. KM Biologics Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 126. KM Biologics Main Business Table 127. KM Biologics Latest Developments Table 128. ADIMMUNE Corporation Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors Table 129. ADIMMUNE Corporation Multivalent Influenza Vaccines Product Portfolios and Specifications Table 130. ADIMMUNE Corporation Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 131. ADIMMUNE Corporation Main Business Table 132. ADIMMUNE Corporation Latest Developments Table 133. Aleph Biomedical Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors Table 134. Aleph Biomedical Multivalent Influenza Vaccines Product Portfolios and Specifications Table 135. Aleph Biomedical Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 136. Aleph Biomedical Main Business Table 137. Aleph Biomedical Latest Developments Table 138. Shanghai Institute of Biological Products Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors Table 139. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Portfolios and Specifications Table 140. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 141. Shanghai Institute of Biological Products Main Business Table 142. Shanghai Institute of Biological Products Latest Developments Table 143. Zhongyianke Biotech Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors Table 144. Zhongyianke Biotech Multivalent Influenza Vaccines Product Portfolios and Specifications Table 145. Zhongyianke Biotech Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 146. Zhongyianke Biotech Main Business Table 147. Zhongyianke Biotech Latest Developments Table 148. Wuhan Institute of Biological Products Basic Information, Multivalent Influenza Vaccines Manufacturing Base, Sales Area and Its Competitors Table 149. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Portfolios and Specifications Table 150. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 151. Wuhan Institute of Biological Products Main Business Table 152. Wuhan Institute of Biological Products Latest Developments List of Figures Figure 1. Picture of Multivalent Influenza Vaccines Figure 2. Multivalent Influenza Vaccines Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global Multivalent Influenza Vaccines Sales Growth Rate 2020-2031 (K Units) Figure 7. Global Multivalent Influenza Vaccines Revenue Growth Rate 2020-2031 ($ millions) Figure 8. Multivalent Influenza Vaccines Sales by Geographic Region (2020, 2024 & 2031) & ($ millions) Figure 9. Multivalent Influenza Vaccines Sales Market Share by Country/Region (2024) Figure 10. Multivalent Influenza Vaccines Sales Market Share by Country/Region (2020, 2024 & 2031) Figure 11. Product Picture of Trivalent Inactivated Influenza Vaccine (IIV3) Figure 12. Product Picture of Trivalent Live Attenuated Vaccine (LAIV3) Figure 13. Product Picture of Quadrivalent Inactivated Influenza Vaccine (IIV4) Figure 14. Global Multivalent Influenza Vaccines Sales Market Share by Type in 2025 Figure 15. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2020-2025) Figure 16. Multivalent Influenza Vaccines Consumed in 6 Months to 3 Years Figure 17. Global Multivalent Influenza Vaccines Market: 6 Months to 3 Years (2020-2025) & (K Units) Figure 18. Multivalent Influenza Vaccines Consumed in Above 3 Years Figure 19. Global Multivalent Influenza Vaccines Market: Above 3 Years (2020-2025) & (K Units) Figure 20. Global Multivalent Influenza Vaccines Sale Market Share by Application (2024) Figure 21. Global Multivalent Influenza Vaccines Revenue Market Share by Application in 2025 Figure 22. Multivalent Influenza Vaccines Sales by Company in 2025 (K Units) Figure 23. Global Multivalent Influenza Vaccines Sales Market Share by Company in 2025 Figure 24. Multivalent Influenza Vaccines Revenue by Company in 2025 ($ millions) Figure 25. Global Multivalent Influenza Vaccines Revenue Market Share by Company in 2025 Figure 26. Global Multivalent Influenza Vaccines Sales Market Share by Geographic Region (2020-2025) Figure 27. Global Multivalent Influenza Vaccines Revenue Market Share by Geographic Region in 2025 Figure 28. Americas Multivalent Influenza Vaccines Sales 2020-2025 (K Units) Figure 29. Americas Multivalent Influenza Vaccines Revenue 2020-2025 ($ millions) Figure 30. APAC Multivalent Influenza Vaccines Sales 2020-2025 (K Units) Figure 31. APAC Multivalent Influenza Vaccines Revenue 2020-2025 ($ millions) Figure 32. Europe Multivalent Influenza Vaccines Sales 2020-2025 (K Units) Figure 33. Europe Multivalent Influenza Vaccines Revenue 2020-2025 ($ millions) Figure 34. Middle East & Africa Multivalent Influenza Vaccines Sales 2020-2025 (K Units) Figure 35. Middle East & Africa Multivalent Influenza Vaccines Revenue 2020-2025 ($ millions) Figure 36. Americas Multivalent Influenza Vaccines Sales Market Share by Country in 2025 Figure 37. Americas Multivalent Influenza Vaccines Revenue Market Share by Country (2020-2025) Figure 38. Americas Multivalent Influenza Vaccines Sales Market Share by Type (2020-2025) Figure 39. Americas Multivalent Influenza Vaccines Sales Market Share by Application (2020-2025) Figure 40. United States Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 41. Canada Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 42. Mexico Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 43. Brazil Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 44. APAC Multivalent Influenza Vaccines Sales Market Share by Region in 2025 Figure 45. APAC Multivalent Influenza Vaccines Revenue Market Share by Region (2020-2025) Figure 46. APAC Multivalent Influenza Vaccines Sales Market Share by Type (2020-2025) Figure 47. APAC Multivalent Influenza Vaccines Sales Market Share by Application (2020-2025) Figure 48. China Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 49. Japan Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 50. South Korea Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 51. Southeast Asia Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 52. India Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 53. Australia Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 54. China Taiwan Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 55. Europe Multivalent Influenza Vaccines Sales Market Share by Country in 2025 Figure 56. Europe Multivalent Influenza Vaccines Revenue Market Share by Country (2020-2025) Figure 57. Europe Multivalent Influenza Vaccines Sales Market Share by Type (2020-2025) Figure 58. Europe Multivalent Influenza Vaccines Sales Market Share by Application (2020-2025) Figure 59. Germany Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 60. France Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 61. UK Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 62. Italy Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 63. Russia Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 64. Middle East & Africa Multivalent Influenza Vaccines Sales Market Share by Country (2020-2025) Figure 65. Middle East & Africa Multivalent Influenza Vaccines Sales Market Share by Type (2020-2025) Figure 66. Middle East & Africa Multivalent Influenza Vaccines Sales Market Share by Application (2020-2025) Figure 67. Egypt Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 68. South Africa Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 69. Israel Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 70. Turkey Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 71. GCC Countries Multivalent Influenza Vaccines Revenue Growth 2020-2025 ($ millions) Figure 72. Manufacturing Cost Structure Analysis of Multivalent Influenza Vaccines in 2025 Figure 73. Manufacturing Process Analysis of Multivalent Influenza Vaccines Figure 74. Industry Chain Structure of Multivalent Influenza Vaccines Figure 75. Channels of Distribution Figure 76. Global Multivalent Influenza Vaccines Sales Market Forecast by Region (2026-2031) Figure 77. Global Multivalent Influenza Vaccines Revenue Market Share Forecast by Region (2026-2031) Figure 78. Global Multivalent Influenza Vaccines Sales Market Share Forecast by Type (2026-2031) Figure 79. Global Multivalent Influenza Vaccines Revenue Market Share Forecast by Type (2026-2031) Figure 80. Global Multivalent Influenza Vaccines Sales Market Share Forecast by Application (2026-2031) Figure 81. Global Multivalent Influenza Vaccines Revenue Market Share Forecast by Application (2026-2031)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Sanofi|||CSL|||GSK|||Viatris|||AstraZeneca|||Hualan Bio|||Changchun Institute of Biological|||Sinovac|||Bcht Biotechnology|||Jiangsu GDK|||KM Biologics|||ADIMMUNE Corporation|||Aleph Biomedical|||Shanghai Institute of Biological Products|||Zhongyianke Biotech|||Wuhan Institute of Biological Products